City Therapeutics Announces First Participant Dosed in Phase 1 Clinical Trial of CITY-RBP4 for the Treatment of Stargardt Disease
Globe Newswire•10/11/2026•07:00 ET
0
Key Highlights
- ➤CITY-RBP4 enters Phase 1 after first participant dosing for Stargardt disease
- ➤Initial Phase 1 data expected in mid-2027
- ➤City now has two programs in clinical development
- ➤Third program expected to enter the clinic through an investigator-initiated trial by year-end
Expert Statements
Andy Orth, President and Chief Executive Officer of City Therapeutics
“Stargardt disease is a devastating condition that can lead to significant vision loss early in life, yet there are currently no approved treatments.”
Andy Orth, President and Chief Executive Officer of City Therapeutics
“Advancing CITY-RBP4 into the clinic brings us an important step closer to addressing that unmet need, while also reflecting the significant progress of our pipeline.”
Andy Orth, President and Chief Executive Officer of City Therapeutics
“With two programs now in the clinic and a third program expected to enter the clinic through an investigator-initiated trial by year-end, we continue to leverage our City Platform to develop RNAi therapeutics designed to deliver meaningful and durable benefits for patients in need.”
Andy Orth, President and Chief Executive Officer of City Therapeutics
“We look forward to evaluating CITY-RBP4’s therapeutic potential in this Phase 1 study and reporting initial data in mid-2027.”
CITY-RBP4 is an RNAi therapeutic candidate designed to provide potent and durable suppression of RBP4, a clinically supported target in Stargardt disease
City’s second program to advance into the clinic, demonstrating strong momentum across the pipeline
Get started
Create a free account to read the full story.